Prothrombotic Mutations, Hormone Therapy, and Venous Thromboembolism Among Postmenopausal Women

Abstract

In contrast to oral estrogen, transdermal estrogen does not confer additional risk on women who carry a prothrombotic mutation. The safety of transdermal estrogen has to be confirmed in randomized trials.